Glipizide Use in Patients with Impaired Kidney Function

Dosing Recommendations for Renal Impairment

In patients with moderate‑to‑severe chronic kidney disease (eGFR 30–45 mL/min/1.73 m²), glipizide can be used but requires dose reduction and close glucose monitoring to mitigate hypoglycemia risk. 1
When eGFR falls below 30 mL/min/1.73 m², glipizide (a hepatically metabolized sulfonylurea) still may be prescribed, but the dose should be reduced and titrated cautiously because renal clearance is markedly decreased. 1
Initiation of glipizide in patients with eGFR < 30 mL/min/1.73 m² should start at approximately 2.5 mg once daily, with slow upward titration (2.5–5 mg increments) at intervals of several days, guided by self‑monitored blood glucose. 4

Glyburide (glybuzide) should be avoided in any degree of renal impairment because its active metabolites accumulate and cause prolonged hypoglycemia; this recommendation is supported by nephrology literature. 1
The American Diabetes Association (2025) advises that glyburide be avoided in older adults, whereas glipizide—being shorter‑acting—may be used with appropriate monitoring. 3
Glipizide’s shorter duration of action, relative to glyburide, reduces the likelihood of prolonged hypoglycemia, making it the preferred sulfonylurea in renal disease. 3

For any patient with renal impairment receiving a sulfonylurea, blood glucose should be checked at every clinical visit to detect hypoglycemia early. 3
During initiation and dose adjustments, especially in patients aged ≥ 65 years, glucose monitoring should be performed frequently because older adults have a > 3‑fold higher risk of hypoglycemia. (Evidence from cohort analyses; citation @3)

Glipizide should be temporarily stopped during acute illness, dehydration, or when patients are prescribed fluoroquinolones or trimethoprim‑sulfamethoxazole, as these agents increase sulfonylurea exposure and precipitate hypoglycemia. 3

DPP‑4 inhibitors—particularly linagliptin, which requires no dose adjustment—are considered safer alternatives for patients with low eGFR and high hypoglycemia risk. 3
Repaglinide can be initiated at 0.5 mg before meals in patients with eGFR < 30 mL/min/1.73 m² and provides greater dosing flexibility than glipizide. 4

Glipizide’s hepatic metabolism and relatively short half‑life make it distinctly safer than renally cleared sulfonylureas, which generate active metabolites that accumulate in kidney disease. 1